What Hologic Filed About the Blackstone and TPG Take-Private

Hologic filed on 7 April 2026 that funds managed by Blackstone and TPG had completed their acquisition of the company, with stockholders receiving 76 dollars per share in cash plus a non-tradable contingent value right of up to 3 dollars paid in two instalments of up to 1.50 dollars each if the Breast Health business hits global revenue goals in fiscal 2026 and 2027. The filing says the common stock has ceased trading and will be delisted from Nasdaq, names a wholly owned subsidiary of the Abu Dhabi Investment Authority and an affiliate of GIC as minority investors, and says Jose E. Almeida became chief executive on completion, succeeding Stephen MacMillan after more than 12 years. The deal was first announced on 21 October 2025 at an enterprise value of up to 18.3 billion dollars, and stockholders approved it on 5 February 2026.

Why the Hologic Take-Private Matters to Breast Imaging Buyers

A health system comparing imaging vendors has been using Hologic's quarterly filings to judge whether the company can keep supporting a 10-year equipment estate. Those filings are gone. The contingent value right is also worth reading: part of the price depends on the Breast Health business hitting revenue goals in fiscal 2026 and 2027, which is the same business that sells the AI software, so the owners have a reason to push sales hard in exactly that window. None of that says the products will get worse, but it does mean a buyer should put support and upgrade commitments in the contract rather than trusting a public track record.

Where the Hologic Update Comes From

Hologic SEC filing is the original record behind this update. It tells us what the company published. This brief adds the market context and the method we would use to test the development against other evidence.

Hologic SEC filing original source.

How We Would Research the Hologic Take-Private

The source gives us the starting point. This is how we would build the next layer of research around it.

  1. We would ask Hologic directly for the service and software update commitments in writing, since the quarterly filings that used to answer that question have stopped.
  2. Then we would read the contingent value right terms in the 8-K to see which revenue goals the new owners are being paid on, because that shapes how the sales team will behave through fiscal 2027.
  3. We would check whether our own support contact and escalation path survived the leadership change, rather than assuming the account team is the same.